A Phase 1 Non- Randomized Open Label Sequential Group Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2014
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Apr 2011 Results reported in Hepatology.
- 13 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.